State of Wyoming Buys 10,715 Shares of Bruker Corporation $BRKR

State of Wyoming bought a new stake in Bruker Corporation (NASDAQ:BRKR) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,715 shares of the medical research company’s stock, valued at approximately $694,000.

A number of other institutional investors have also recently made changes to their positions in the company. Essential Partners LLC bought a new position in shares of Bruker during the 1st quarter worth $36,000. Global Retirement Partners LLC purchased a new stake in Bruker in the 2nd quarter worth about $38,000. EverSource Wealth Advisors LLC increased its holdings in Bruker by 532.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,500 shares of the medical research company’s stock worth $54,000 after acquiring an additional 1,263 shares during the last quarter. Root Financial Partners LLC bought a new stake in Bruker in the 3rd quarter valued at about $57,000. Finally, FNY Investment Advisers LLC bought a new stake in Bruker in the 2nd quarter valued at about $60,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on BRKR shares. JPMorgan Chase & Co. downgraded shares of Bruker from an “overweight” rating to a “neutral” rating and set a $60.00 price objective on the stock. in a report on Wednesday, October 14th. Zacks Research downgraded shares of Bruker from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 2nd. UBS Group started coverage on shares of Bruker in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $65.00 target price for the company. Citigroup lowered their price target on shares of Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a research report on Wednesday, August 5th. Finally, The Goldman Sachs Group upgraded shares of Bruker from a “strong sell” rating to a “strong-buy” rating in a research note on Monday, September 21st. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $59.43.

Insider Buying and Selling at Bruker

In other news, VP Mark Munch sold 2,000 shares of the stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the sale, the vice president directly owned 134,806 shares of the company’s stock, valued at approximately $7,127,193.22. This represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 27.20% of the stock is currently owned by corporate insiders.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $57.07 on Friday. The stock has a market cap of $8.70 billion, a PE ratio of -81.53, a price-to-earnings-growth ratio of 1.75 and a beta of 1.22. Bruker Corporation has a fifty-two week low of $32.37 and a fifty-two week high of $66.98. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. The stock has a fifty day moving average of $58.90 and a 200-day moving average of $50.35.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. The company had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st were given a dividend of $0.05 per share. The ex-dividend date was Monday, September 21st. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s dividend payout ratio is currently -28.57%.

Bruker Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.